614MO A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)

Category Primary study
JournalAnnals of Oncology
Year 2024
This article has no abstract
Epistemonikos ID: 36b61c33d5609439f04f73496676bb04d6eaccd1
First added on: Feb 19, 2025